Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;93(1):569-572.
doi: 10.1002/jmv.26363. Epub 2020 Aug 26.

Clinical validation of an immunochromatographic SARS-Cov-2 IgM/IgG antibody assay with Japanese cohort

Shun Kaneko  1 , Yoko Nukui  2 , Takeshi Arashiro  2 , Yoshibumi Aiso  2 , Maya Sugii  2 , Yoshiro Hadano  2 , Kaoru Nagata  3 , Reiko Taki  4 , Ken Ueda  3 , Satoko Hanada  4 , Shinichiro Suzaki  5 , Naoshige Harada  5 , Yoshimi Yamaguchi  6 , Hiroyuki Nakanishi  1 , Masayuki Kurosaki  1 , Masayuki Nagasawa  7 , Namiki Izumi  1
Affiliations

Clinical validation of an immunochromatographic SARS-Cov-2 IgM/IgG antibody assay with Japanese cohort

Shun Kaneko et al. J Med Virol. 2021 Jan.

Abstract

Background: The coronavirus disease 2019 (COVID-19) has become a major health threat. To overcome COVID-19, appropriate diagnosis methods are urgently needed. The aim of this study was to clinically evaluate the colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG antibody (Ab).

Methods: Patients confirmed COVID-19 (n = 51) were recruited prospectively from the Musashino Red Cross hospital and Tokyo Medical and Dental University Medical Hospital, between March and May 2020. And the analytical specificity was assessed with serum samples of patients without COVID-19 (n = 100) collected between August to September 2019 before SARS-CoV-2 was first reported in China.

Results: Among COVID-19 patients, a total of 87 serum samples were tested for SARS-Cov-2 IgM/IgG Ab assay. IgM was detected 71.0 %, 86.9 %, and 83.3 % at day8-14, 15-28, >29 after symptom onset and IgG was detected in 81.6 %, 87.0 %, and 94.4 %, respectively. The sensitivity of IgM and IgG Ab after day8 assay was significantly higher than before day7, respectively (p=0.0016, 0.0003). There were no positive results in 100 serum samples from patients without COVID-19.

Conclusion: The SARS-Cov-2 IgM/IgG Ab assay had 79.7% / 86.1% sensitivity (the 8 days after from onset) and 100% specificity in this population.

Keywords: COVID-19; SARS-Cov-2 IgM/IgG antibody; colloidal gold immunochromatography assay.

PubMed Disclaimer

References

REFERENCES

    1. World Health Organization. Coronavirus disease (COVID-19). Situation Report-140. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2.... Accessed June 9, 2020.
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
    1. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-e25.

Publication types

LinkOut - more resources